Skip to main content

Table 3 Erythrocyte deformability – elongation index (EI) at different shear stress rates at baseline and after 12 and 24 weeks of treatment in both treatment groups

From: Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus – results from an exploratory study

  Baseline 12 weeks 24 weeks
Shear stress (Pa) Glimepiride Vildagliptin Glimepiride Vildagliptin Glimepiride Vildagliptin
0.3 0.65 ± 0.68 0.86 ± 0.45 0.93 ± 0.80 0.87 ± 0.63 1.65 ± 1.40 * 1.54 ± 0.91 *
0.6 2.66 ± 1.14 2.55 ± 1.24 2.37 ± 1.37 2.65 ± 1.34 3.76 ± 2.13 3.67 ± 1.73 *
1.2 8.53 ± 2.25 8.80 ± 2.00 7.96 ± 2.38 8.79 ± 2.29 10.11 ± 2.66 * 10.24 ± 2.90 *
3 20.89 ± 3.60 21.71 ± 3.24 20.09 ± 3.68 21.53 ± 3.28 24.13 ± 3.74 * 23.95 ± 3.14 *
6 30.50 ± 3.95 31.33 ± 3.45 29.81 ± 4.17 31.15 ± 3.25 33.80 ± 4.13 * 33.20 ± 3.32 *
12 38.62 ± 4.01 39.36 ± 3.34 37.95 ± 4.33 39.28 ± 3.02 41.37 ± 4.12 * 40.59 ± 3.33 *
30 46.43 ± 3.86 47.07 ± 3.38 45.94 ± 4.47 47.14 ± 2.82 48.80 ± 4.13 * 47.71 ± 3.59
60 50.12 ± 3.86 50.75 ± 3.48 49.70 ± 4.36 50.89 ± 2.97 52.69 ± 4.25 * 51.32 ± 4.05
  1. mean ± SD; * = p < 0.05 vs. baseline.